Dalteparin (Fragmin)

Dalteparin, marketed under the brand name Fragmin, is a low molecular weight heparin that serves as an important anticoagulant medication in feline medicine. This injectable medication belongs to the class of antithrombotic agents and is used to prevent and treat blood clots in cats at risk for or affected by thromboembolic disease. Dalteparin has gained recognition in veterinary cardiology as a valuable option for acute anticoagulation in cats with arterial thromboembolism and for ongoing thrombosis prevention in high-risk patients. As a low molecular weight heparin, dalteparin offers several advantages over traditional unfractionated heparin, including more predictable anticoagulant effects and the ability to be administered at home by trained pet owners.

The mechanism of action of dalteparin involves potentiation of antithrombin III, a natural anticoagulant protein in the blood. When dalteparin binds to antithrombin III, it dramatically enhances this protein's ability to inhibit clotting factors, particularly factor Xa and to a lesser extent thrombin. This inhibition of the coagulation cascade prevents the formation of new blood clots and limits the extension of existing clots. Unlike unfractionated heparin, dalteparin has a higher ratio of anti-Xa to anti-thrombin activity, which contributes to its more predictable dose response. The anticoagulant effect begins rapidly after subcutaneous injection, with peak anti-Xa activity typically occurring within three to five hours.

Dalteparin is available as a sterile injectable solution in various concentrations for subcutaneous administration. The medication comes in pre-filled syringes or multi-dose vials containing different unit strengths. For feline patients, the small volumes required for appropriate dosing necessitate careful measurement, often using insulin syringes for accuracy. Administration is performed subcutaneously, typically in the scruff of the neck or along the lateral thorax or abdomen. The subcutaneous route allows for at-home administration by owners who have been properly trained by their veterinary team, making long-term anticoagulation therapy feasible for some cats. Injection frequency varies based on the clinical situation but typically ranges from once to twice daily.

The safety profile of dalteparin in cats requires careful consideration of bleeding risks inherent to any anticoagulant therapy. When properly dosed and monitored, many cats tolerate dalteparin therapy well, though the risk of hemorrhage is always present with anticoagulant medications. Regular veterinary monitoring is essential for cats receiving dalteparin, particularly during initial therapy when dose adjustments may be needed. Pet owners must understand the commitment required for injectable medication administration and be prepared to monitor their cat for signs of bleeding or other adverse effects. The decision to use dalteparin involves weighing the significant risks of thromboembolism against the bleeding risks of anticoagulation, a balance that the veterinary team helps navigate.

The primary indication for dalteparin in cats is the treatment and prevention of thromboembolism, particularly arterial thromboembolism associated with feline cardiac disease. Cats with hypertrophic cardiomyopathy and other forms of heart disease are at significant risk for developing blood clots that can travel to distant arteries, most commonly lodging at the aortic bifurcation and causing the devastating condition known as saddle thrombus. Dalteparin may be used as part of acute treatment protocols for cats presenting with arterial thromboembolism, helping to prevent clot extension and formation of additional thrombi during the critical early period. The medication is considered an important tool in the acute management of feline ATE.

In the acute thromboembolism setting, dalteparin is often initiated in hospitalized cats to provide rapid anticoagulation while other supportive treatments are administered. The goal of anticoagulant therapy in acute ATE is to prevent the existing clot from growing larger, prevent new clots from forming, and allow the body's natural fibrinolytic mechanisms to gradually dissolve the obstruction. Dalteparin provides more predictable anticoagulation than unfractionated heparin, which can be advantageous in the unstable ATE patient. The medication is typically used alongside pain management, supportive care, and other treatments directed at the specific complications of thromboembolism.

Beyond acute treatment, dalteparin may be prescribed for ongoing thromboembolism prevention in cats with high-risk cardiac conditions. While oral antiplatelet agents like clopidogrel are more commonly used for long-term prophylaxis due to ease of administration, some veterinary cardiologists recommend low molecular weight heparins for cats deemed at very high risk for thromboembolism. Cats with severe left atrial enlargement, spontaneous echocardiographic contrast in the heart, or previous thromboembolism events may be candidates for dalteparin therapy. The injectable nature of the medication limits its practical use for long-term prevention in many cases, but dedicated owners willing to perform daily injections may find it a viable option.

Dalteparin may also be used in cats with venous thromboembolic disease, though arterial thromboembolism is far more common in feline patients. Cats with indwelling catheters, severe illness, or conditions predisposing to venous stasis may rarely develop venous thrombosis. In human medicine, low molecular weight heparins are standard treatment for deep vein thrombosis and pulmonary embolism, and similar applications exist in veterinary medicine when these conditions occur. Additionally, dalteparin may be considered perioperatively in cats with cardiac disease undergoing surgical procedures to reduce thrombotic risk during the high-risk perioperative period.

When selecting dalteparin over alternative anticoagulants or antiplatelet agents, veterinarians consider multiple factors including the acuity of the clinical situation, the severity of thrombotic risk, owner ability to administer injections, and cost considerations. Dalteparin may be preferred over unfractionated heparin for at-home use due to its more predictable pharmacokinetics and once or twice daily dosing. Compared to oral antiplatelet agents, dalteparin provides more potent anticoagulation but requires injection and carries higher bleeding risk. The choice of antithrombotic therapy is individualized for each patient based on their specific clinical circumstances and the owner's capabilities for medication administration.

Dosing of dalteparin in cats requires careful veterinary calculation based on the individual patient's weight, clinical condition, and intended use. The specific dose prescribed will vary depending on whether the medication is being used for acute thromboembolism treatment or ongoing prevention. Dalteparin doses are measured in international units based on anti-Xa activity, and precise measurement is essential due to the potent anticoagulant effects of the medication. Pet owners should never adjust the dose without explicit direction from the veterinarian, as both underdosing and overdosing carry significant risks.

General dosing guidelines for dalteparin in cats vary among references and clinical protocols, with commonly cited ranges for prevention and treatment purposes. Treatment doses for acute thromboembolism may be higher than doses used for prophylaxis. The typical dosing frequency is once or twice daily depending on the clinical situation and veterinary preference. Some protocols recommend more frequent initial dosing followed by reduction to once daily for maintenance. Because dalteparin pharmacokinetics in cats are not as thoroughly characterized as in humans, veterinarians often rely on published feline studies and clinical experience to guide dosing decisions.

Treatment duration for dalteparin varies considerably based on the clinical indication. In acute thromboembolism, dalteparin may be used for several days to weeks during hospitalization and initial recovery, often until the cat is transitioned to oral antiplatelet therapy for long-term management. For ongoing prevention in very high-risk cats, treatment may continue indefinitely, though the practical challenges of long-term injectable therapy limit this approach. The veterinary team will establish a treatment timeline and transition plan based on the individual cat's response and circumstances.

Administration of dalteparin requires proper training in subcutaneous injection technique. The veterinary team will demonstrate the correct method for drawing up the precise dose and injecting it under the cat's skin. Injection sites should be rotated to prevent localized reactions and tissue damage. The scruff of the neck and lateral body wall are common injection sites in cats. Small gauge needles and insulin syringes are typically used to measure the small volumes needed for feline patients. Pet owners should be comfortable with the injection process before taking over home administration, and return demonstrations to the veterinary staff help ensure proper technique.

Missed doses of dalteparin should be handled according to veterinary guidance, as the appropriate response may depend on the specific clinical situation. Generally, if a dose is missed and it is noticed within a few hours, the dose may be given late. However, if it is close to the time for the next scheduled dose, owners should consult with their veterinarian about whether to skip the missed dose or adjust the timing. Double doses should never be given, as this significantly increases bleeding risk. Owners who miss multiple doses or have concerns about their administration technique should contact their veterinary team promptly.

Consistent administration of dalteparin as prescribed is essential for maintaining appropriate anticoagulation. Stopping the medication abruptly without veterinary guidance could leave a cat vulnerable to thromboembolism, while irregular dosing could result in unpredictable anticoagulation levels. If concerns arise about the medication's efficacy, side effects, or the owner's ability to continue injections, these should be discussed with the veterinarian so that the treatment plan can be appropriately modified. Transition to alternative antithrombotic therapy should be done under veterinary supervision to maintain protection during the changeover period.

Dalteparin is associated with a significant risk of bleeding complications, which represents the most important category of side effects for this anticoagulant medication. The therapeutic effect of preventing blood clot formation inherently means that the body's ability to stop bleeding is impaired. Pet owners must understand this fundamental trade-off and be vigilant for signs of excessive bleeding while their cat is receiving dalteparin therapy. The veterinary team carefully weighs the risk of bleeding against the risk of thromboembolism when prescribing this medication, and ongoing monitoring helps ensure that the balance remains appropriate.

The most commonly observed adverse effects of dalteparin in cats involve bleeding of varying severity. Minor bleeding may manifest as prolonged bleeding from injection sites, blood in the urine appearing pink or red, or small amounts of blood in stool. More significant bleeding can include visible bruising under the skin, bleeding gums, nosebleeds, blood in vomit, or dark tarry stools indicating gastrointestinal hemorrhage. These signs should be reported to the veterinarian promptly so that the dose can be adjusted or the medication discontinued if necessary. Most minor bleeding events resolve with dose modification, but significant hemorrhage may require more intensive intervention.

Injection site reactions represent another category of side effects seen with dalteparin use. Because the medication is administered subcutaneously, the injection sites may develop localized reactions including bruising, swelling, pain, or hardening of the tissue. Rotating injection sites helps minimize these local effects by allowing previously used areas to recover. In rare cases, more significant skin reactions or tissue necrosis at injection sites can occur. Pet owners should inspect injection sites regularly and report any concerning changes to the veterinary team. Proper injection technique and site rotation are important for minimizing local adverse effects.

Thrombocytopenia, a decrease in platelet count, is a recognized complication of heparin-type anticoagulants in humans and may occur in cats receiving dalteparin. Heparin-induced thrombocytopenia can paradoxically increase clotting risk despite the anticoagulant therapy and represents a serious adverse effect requiring medication discontinuation. While this complication appears to be rare in cats, platelet count monitoring may be recommended for cats receiving prolonged dalteparin therapy. Signs of severe thrombocytopenia may include increased bleeding tendency or new clot formation despite anticoagulation.

Severe adverse effects requiring immediate veterinary attention include signs of major hemorrhage such as weakness, pale gums, rapid breathing, collapse, or abdominal distension that could indicate internal bleeding. Any sudden neurological changes including seizures, severe disorientation, or paralysis could potentially indicate bleeding within the brain or spinal cord. Cats showing signs of anaphylactic reaction such as facial swelling, difficulty breathing, vomiting, or collapse need emergency care. Additionally, the sudden onset of hind limb paralysis or pain in a cat on dalteparin therapy could indicate a new thromboembolism despite treatment, which requires immediate veterinary evaluation. Pet owners should have emergency contact information readily available and know the location of the nearest emergency veterinary facility.

Dalteparin should not be administered to cats with known hypersensitivity to dalteparin, heparin, other low molecular weight heparins, or any component of the formulation. Allergic reactions to heparin products can be severe and potentially life-threatening, so any history of previous adverse reactions to this class of medications is a significant contraindication. Pork allergy may be relevant as dalteparin is derived from porcine intestinal mucosa. Pet owners should inform the veterinarian of any known drug allergies or previous reactions to injectable medications before dalteparin therapy is initiated.

Active bleeding or conditions associated with high bleeding risk represent major contraindications to dalteparin use. Cats with ongoing hemorrhage from any source, including gastrointestinal bleeding, bleeding tumors, recent trauma with blood loss, or post-surgical bleeding, should not receive dalteparin as it would exacerbate blood loss. Additionally, cats with known bleeding disorders such as hemophilia, von Willebrand disease, or severe thrombocytopenia are generally not candidates for anticoagulant therapy. The presence of conditions that increase bleeding risk, such as known gastric ulceration or recent surgery, may be relative contraindications requiring careful risk-benefit assessment.

Severe kidney disease affects dalteparin clearance and may be a contraindication or require significant dose adjustment. Low molecular weight heparins are primarily eliminated through the kidneys, so cats with severe renal impairment may accumulate the drug and experience excessive anticoagulation. Given the high prevalence of chronic kidney disease in older cats, renal function assessment is important before initiating dalteparin therapy. Cats with mild to moderate kidney disease may still receive dalteparin with appropriate monitoring and possible dose reduction, but severe renal failure may preclude safe use. The veterinary team will evaluate kidney function as part of the pre-treatment assessment.

The safety of dalteparin in pregnant cats has not been established, and the medication should generally be avoided during pregnancy unless the benefits clearly outweigh potential risks. While heparin products do not cross the placenta and are not considered teratogenic, the risk of bleeding complications during pregnancy and delivery is a concern. Lactating cats may receive dalteparin as it is not expected to be present in milk in significant amounts, but caution is still warranted. Use in breeding animals should be carefully considered. Very young kittens should not receive dalteparin unless absolutely necessary, as dosing guidelines for pediatric feline patients are not established. Cats scheduled for surgery should have dalteparin discontinued prior to the procedure, with timing depending on the specific surgical requirements, to reduce perioperative bleeding risk.

Complete disclosure of all medications, supplements, and treatments a cat is receiving is essential before starting dalteparin therapy. Drug interactions with anticoagulants can significantly increase bleeding risk or occasionally reduce anticoagulant efficacy, both of which can have serious consequences. Because dalteparin is often used in critically ill cats who may be receiving multiple medications, careful attention to potential interactions is particularly important. The veterinary team will review all concurrent treatments to identify and manage potential interactions.

Concurrent use of other anticoagulant or antiplatelet medications with dalteparin substantially increases bleeding risk. Combination with aspirin, clopidogrel, or other antiplatelet agents creates additive or synergistic inhibition of hemostasis. While some clinical situations may warrant combined antithrombotic therapy, this significantly increases hemorrhagic risk and requires careful monitoring. Other anticoagulants including warfarin, unfractionated heparin, or other low molecular weight heparins should not generally be combined with dalteparin. If transitioning between anticoagulants is necessary, the veterinary team will manage the overlap period to minimize both bleeding and thrombotic risk.

Non-steroidal anti-inflammatory drugs such as meloxicam or carprofen can increase bleeding risk when used with dalteparin through their effects on platelet function and potential for gastrointestinal irritation. While pain management is often important in cats with thromboembolism, the choice of analgesic must consider the concurrent anticoagulant therapy. Opioid pain medications are often preferred in cats receiving dalteparin because they do not affect platelet function. Corticosteroids may also increase bleeding risk in some cases and can cause gastrointestinal ulceration, so concurrent use with dalteparin warrants monitoring.

Certain supplements and herbal products have anticoagulant or antiplatelet properties that could interact with dalteparin therapy. Fish oil supplements containing omega-3 fatty acids have mild antiplatelet effects and could theoretically increase bleeding risk when combined with dalteparin. Vitamin E at high doses can impair clotting, as can certain herbal supplements including garlic, ginkgo, and ginger. Pet owners should disclose all supplements their cat receives, including those that seem benign, so the veterinary team can assess cumulative effects on coagulation.

Monitoring for drug interactions during dalteparin therapy involves clinical observation for signs of bleeding and potentially laboratory testing. Any increase in bruising, prolonged bleeding from minor wounds, or evidence of internal bleeding should prompt evaluation for possible drug interactions. Anti-Xa level monitoring, when available, can help assess anticoagulation status and identify cases where drug interactions may be affecting dalteparin activity. Pet owners should promptly inform the veterinary team of any new medications or supplements started during dalteparin therapy, and should not add any new treatments without veterinary approval given the bleeding risk concerns.

General precautions for dalteparin use in cats include careful attention to dosing accuracy, injection technique, and monitoring for adverse effects. The potent anticoagulant effects of dalteparin mean that dosing errors can have significant consequences, so precise measurement of each dose is essential. Pet owners must be thoroughly trained in proper injection technique before beginning home administration, and ongoing compliance with the prescribed regimen is crucial for therapeutic success. Regular communication with the veterinary team helps ensure that any concerns are addressed promptly.

While breed-specific sensitivities to dalteparin have not been documented in cats, individual variation in response to anticoagulation exists and may influence outcomes. Some cats may be more sensitive to dalteparin's anticoagulant effects, experiencing more pronounced bleeding tendency at standard doses, while others may require higher doses for adequate effect. Breeds predisposed to hypertrophic cardiomyopathy, such as Maine Coons, Ragdolls, and British Shorthairs, may be more likely to require dalteparin therapy due to their cardiac disease risk, but do not appear to have breed-related differences in drug response. Close monitoring during initial therapy helps identify individual variation and allows for appropriate dose adjustment.

Safe handling of dalteparin requires attention to proper injection supply disposal and medication storage. Used needles and syringes should be disposed of in an approved sharps container, never in regular household trash where they could cause injury. Accidental needlestick injuries in humans should receive appropriate medical attention. Multi-dose vials of dalteparin should be handled aseptically to prevent contamination, and any signs of cloudiness, discoloration, or particulate matter indicate the medication should not be used. In households with children or other pets, dalteparin supplies should be stored securely out of reach.

Monitoring during dalteparin treatment should include regular assessment for signs of both efficacy and adverse effects. Pet owners should watch for any evidence of bleeding, including checking injection sites, examining gums for bleeding, and observing urine and stool for blood. Signs that treatment may be working include the absence of new thromboembolism events and improvement in any existing thromboembolic symptoms. Periodic veterinary examinations and potentially laboratory monitoring help assess anticoagulation status and identify any emerging problems. Owners should report any concerning symptoms promptly rather than waiting for scheduled appointments.

Special populations requiring additional caution include geriatric cats, who commonly have concurrent kidney disease that can affect dalteparin elimination, and who may be receiving multiple medications that could interact. Very small cats require particularly precise dosing to avoid excessive anticoagulation. Cats with any degree of hepatic dysfunction may have impaired synthesis of clotting factors, potentially increasing bleeding risk during anticoagulant therapy. Debilitated or severely ill cats may have altered drug distribution and elimination affecting anticoagulant response. Any cat with a history of bleeding complications or gastrointestinal ulceration requires careful consideration before dalteparin is prescribed.

Proper storage of dalteparin is essential to maintain medication stability and ensure consistent therapeutic effects. Dalteparin injectable solution should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit or 20 to 25 degrees Celsius, according to manufacturer guidelines. The medication should not be frozen, as this can affect the formulation's stability and effectiveness. Storage location should be away from direct light and heat sources, in a location where temperature remains relatively stable. A medicine cabinet away from bathrooms and kitchens, where temperature and humidity can fluctuate, is often ideal.

Different dalteparin products may have specific storage requirements that should be carefully followed. Pre-filled syringes and multi-dose vials may have different stability characteristics and beyond-use dates once opened or once the sterile barrier is broken. Multi-dose vials typically have a limited beyond-use period after first puncture, often 28 days, after which any remaining medication should be discarded even if it appears normal. Single-use pre-filled syringes are intended for one-time use and any unused portion should be discarded. Pet owners should note the beyond-use date on all products and mark multi-dose vials with the date of first use. Any dalteparin solution that appears cloudy, discolored, or contains particles should not be used.

Safe handling and disposal of dalteparin and injection supplies is important for household safety and environmental protection. Used needles and syringes must be placed immediately into an approved sharps disposal container and never recapped, bent, or placed in regular trash. Sharps containers can be obtained from pharmacies, veterinary offices, or medical supply stores, and should be sealed and disposed of properly when full according to local regulations. Many communities have medical waste disposal programs that accept sharps containers. Unused or expired dalteparin should not be flushed down the toilet or poured down drains. Drug take-back programs are the preferred disposal method when available. If no take-back option exists, mixing the medication with an unpalatable substance in a sealed container before placing in household trash is an alternative, though liquid medications require additional care in containment.

Dalteparin use in cats is not significantly influenced by breed-specific factors in terms of drug metabolism or sensitivity, as no breed-related differences in response to low molecular weight heparins have been documented in feline patients. However, certain breeds are more likely to require dalteparin therapy due to their predisposition to the cardiac conditions that cause thromboembolism. Understanding breed-related disease prevalence helps veterinarians and owners anticipate which cats may face higher risk and potentially benefit from anticoagulant therapy at some point in their lives.

Breeds with established genetic predisposition to hypertrophic cardiomyopathy include Maine Coons, Ragdolls, British Shorthairs, Persians, Sphynx cats, and Scottish Folds. These breeds may develop HCM at relatively young ages compared to mixed-breed cats, and affected individuals can progress to having left atrial enlargement and thromboembolism risk. Bengal cats, Devon Rex, and Cornish Rex have also shown increased HCM prevalence. Regular cardiac screening is recommended for predisposed breeds, and owners should be educated about the signs of both heart disease and thromboembolism. When cats from these breeds develop high-risk cardiac conditions, dalteparin may be considered as part of their thromboprophylaxis strategy.

Body size considerations affect practical aspects of dalteparin administration in cats. The medication requires precise volumetric measurement for accurate dosing, and very small cats pose particular challenges for dose accuracy. Insulin syringes calibrated in small increments are essential for measuring the tiny volumes often required for feline patients. Large breed cats such as Maine Coons may require larger doses but still within the range of standard injection techniques. Regardless of size, accurate current body weight is important for dose calculation, and weight should be reassessed periodically during ongoing therapy. Very thin or debilitated cats may have different subcutaneous absorption characteristics that could affect drug delivery.

Age-related factors influence dalteparin use across all cat breeds. Young cats and kittens rarely require anticoagulant therapy unless they have congenital cardiac abnormalities, and dosing guidelines for pediatric feline patients are not established. The majority of cats requiring dalteparin are middle-aged to older adults with acquired heart disease. Geriatric cats commonly have concurrent conditions, most notably chronic kidney disease, that affect dalteparin elimination and increase the complexity of therapy. Older cats may also have more fragile blood vessels and decreased platelet function, potentially increasing bleeding risk. The veterinary team will consider the whole patient, including age-related factors, when developing an anticoagulation plan.

Other low molecular weight heparins used in feline medicine include enoxaparin, which is perhaps more commonly referenced in veterinary literature than dalteparin. Enoxaparin and dalteparin have similar mechanisms of action and therapeutic applications, though they differ in their molecular weight distribution and specific anti-Xa to anti-thrombin activity ratios. The choice between low molecular weight heparins often depends on institutional preference, familiarity, available dosing information, and cost considerations. Both medications require subcutaneous injection and carry similar bleeding risks. Unfractionated heparin represents an older anticoagulant option that requires more frequent dosing and monitoring but may be preferred in some acute hospital settings.

Antiplatelet agents represent an alternative pharmacological approach to thromboembolism prevention that differs fundamentally from anticoagulants like dalteparin. Clopidogrel is the most commonly used antiplatelet medication in cats at risk for arterial thromboembolism and works by inhibiting platelet aggregation rather than the coagulation cascade. Aspirin provides antiplatelet effects through cyclooxygenase inhibition. These oral medications are generally preferred for long-term thromboprophylaxis due to ease of administration compared to injectable anticoagulants. The FATCAT study demonstrated clopidogrel's superiority over aspirin for secondary prevention of ATE in cats. Antiplatelet agents may be used following initial dalteparin therapy as cats transition from acute treatment to chronic prevention.

Comprehensive management of cats at risk for thromboembolism typically involves addressing the underlying cardiac disease alongside antithrombotic therapy. Cardiac medications commonly used in cats with cardiomyopathy include beta-blockers such as atenolol to reduce heart rate and myocardial oxygen demand, calcium channel blockers such as diltiazem for similar effects, and diuretics such as furosemide for cats with congestive heart failure. Pimobendan has become increasingly utilized in feline cardiac patients with certain disease phenotypes. ACE inhibitors may be part of management protocols. These cardiac medications work in concert with antithrombotic therapy to address different aspects of the disease process. Owners should never substitute medications without veterinary guidance, as the overall treatment strategy is carefully individualized for each patient's specific cardiac condition and thromboembolic risk profile.